Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€61.66

€61.66

-2.740%
-1.74
-2.740%
-

-

 
12.12.25 / Tradegate WKN: A3ETYB / Name: Sandoz Group / Stock / ? /
Latest predictions
28.10.25
14.23%
buy
Best running prediction
-
28.10.25
14.23%
buy
Your prediction

Sandoz Group AG Stock

We can see a decrease in the price for Sandoz Group AG. Compared to yesterday it has lost -€1.740 (-2.740%).

Pros and Cons of Sandoz Group AG in the next few years

Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases